+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anticoagulants Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797843
The global anti coagulants market size attained a value of USD 34.8 billion in 2022. The market is anticipated to grow at a CAGR of 8.2% during the forecast period of 2023-2031 to attain a value of USD 70.9 billion by 2031.

Anticoagulants Market: Introduction

Anticoagulants are a type of medication used to prevent the formation of blood clots. They work by interfering with the blood clotting process, which can help to prevent dangerous blood clots from forming in the veins or arteries.

Anticoagulants are commonly used to treat a variety of conditions, including deep vein thrombosis, pulmonary embolism, stroke, and heart attack. They are also used to prevent blood clots in individuals who are at high risk, such as those with a history of blood clots or those who are undergoing surgery.

The benefits of anticoagulants are numerous. By preventing the formation of blood clots, anticoagulants can help to reduce the risk of serious complications such as stroke and heart attack. They can also help to improve overall blood flow and reduce the risk of damage to the veins and arteries.

Anticoagulants can be prescribed in various forms, including oral medication and injectable medication. The choice of medication depends on the individual's condition, medical history, and other factors.

It is important to use anticoagulants safely and according to the instructions of a healthcare provider. Overuse or misuse of anticoagulants can lead to adverse side effects, including bleeding and bruising. Regular monitoring of blood tests is often required to ensure that the medication is working properly and to adjust the dosage if necessary.

Overall, anticoagulants are an important tool for preventing blood clots and reducing the risk of serious complications. When used safely and appropriately, they can provide significant benefits for individuals with a variety of conditions.

Anticoagulants Market Segmentations

The market can be categorised into drug class, application, route of administration, distribution channel, and region.

Market Breakup by Drug Class

  • Novel Oral Anticoagulants (NOACs)
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Vitamin K Antagonist

Market Breakup by Application

  • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism
  • Others

Market Breakup by Route of Administration

  • Oral Anticoagulants
  • Injectable Anticoagulants

Market Breakup by Distribution Channel

  • Oral Anticoagulants
  • Injectable Anticoagulants

Anticoagulants Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Anticoagulants Market Scenario

The global market for anticoagulants is expected to experience steady growth in the coming years, driven by the increasing prevalence of conditions such as deep vein thrombosis, pulmonary embolism, stroke, and heart attack, as well as the growing demand for effective prevention and treatment options.

The market for anticoagulants is highly competitive, with many players offering a wide range of products to cater to the diverse needs of healthcare providers and patients. The market is segmented based on product type, application, distribution channel, and geography.

Based on product type, the market is divided into heparin, warfarin, novel oral anticoagulants (NOACs), and others. NOACs are the fastest-growing segment of the market, driven by their effectiveness in preventing and treating blood clots with fewer side effects compared to traditional anticoagulants such as heparin and warfarin.

Based on application, the market is divided into venous thromboembolism, atrial fibrillation, coronary artery disease, and others. Venous thromboembolism is the largest segment of the market, owing to the high prevalence of conditions such as deep vein thrombosis and pulmonary embolism.

Based on distribution channel, the market is divided into hospitals, clinics, retail pharmacies, and online pharmacies. Hospitals are the largest distribution channel segment of the market, owing to the high demand for anticoagulants in acute care settings.

The market for anticoagulants is expected to continue to grow in the coming years, driven by the increasing prevalence of conditions such as deep vein thrombosis, pulmonary embolism, stroke, and heart attack, as well as the growing demand for effective prevention and treatment options. Advances in technology and research are expected to lead to the development of new and innovative anticoagulant products, which may provide more effective options for patients suffering from blood clotting disorders.

Overall, the anticoagulants market is an important component of the healthcare system, providing patients with access to a wide range of prevention and treatment options for blood clotting disorders. When used safely and appropriately, anticoagulants can provide significant benefits for individuals with a variety of conditions.

Key Players in the Global Anticoagulants Market

The report gives an in-depth analysis of the key players involved in the anticoagulants market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Johnson & Johnson Services, Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Aspen Pharmacare Holdings Limited
  • Pfizer Inc
  • Portola Pharmaceuticals, Inc
  • AstraZeneca
  • Aspen Holdings
  • Celgene
  • Armetheon, Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Anticoagulants Market Overview
3.1 Global Anticoagulants Market Historical Value (2016-2022)
3.2 Global Anticoagulants Market Forecast Value (2023-2031)
4 Global Anticoagulants Market Landscape
4.1 Global Anticoagulants Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Anticoagulants Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Application
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Distribution Channel
5 Global Anticoagulants Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Anticoagulants Market Segmentation
6.1 Global Anticoagulants Market by Drug Class
6.1.1 Market Overview
6.1.2 Novel Oral Anticoagulants (NOACs)
6.1.3 Heparin and Low Molecular Weight Heparin (LMWH)
6.1.4 Vitamin K Antagonist
6.2 Global Anticoagulants Market by Application
6.2.1 Market Overview
6.2.2 Atrial Fibrillation/Myocardial Infarction (Heart Attack)
6.2.3 Deep Vein Thrombosis (DVT)
6.2.4 Pulmonary Embolism
6.2.5 Others
6.3 Global Anticoagulants Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral Anticoagulants
6.3.3 Injectable Anticoagulants
6.4 Global Anticoagulants Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Oral Anticoagulants
6.4.3 Injectable Anticoagulants
6.5 Global Anticoagulants Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Anticoagulants Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Anticoagulants Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Anticoagulants Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Anticoagulants Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Anticoagulants Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Johnson & Johnson Services, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bayer AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Boehringer Ingelheim International GmbH
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Bristol-Myers Squibb Company
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Daiichi Sankyo Company, Limited
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 GlaxoSmithKline plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Aspen Pharmacare Holdings Limited
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Portola Pharmaceuticals, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 AstraZeneca
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Aspen Holdings
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Celgene
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Armetheon, Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Anticoagulants Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Aspen Pharmacare Holdings Limited
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Astrazeneca
  • Aspen Holdings
  • Celgene
  • Armetheon, Inc.

Methodology

Loading
LOADING...

Table Information